Collegium Pharmaceutical (COLL) Q1 FY2024 earnings: revenue $145 million, up 0.1% on the year

Collegium Pharmaceutical, Inc. (COLL) reported revenue of $145 million for Q1 FY2024, the quarter ended 31 March 2024, up 0.1% on the same quarter a year earlier. Net income was $28 million, and diluted earnings per share $0.71. The figures are the company's own, from the 10-Q it filed with the SEC on 9 May 2024.

Revenue$145 millionup 0.1%

Net income$28 million

Diluted EPS$0.71

QuarterQ1 FY2024ended 31 March 2024

The quarter, against the one before and a year earlier

Line	Q1 FY2024	Q4 FY2023	A year earlier	Change on the year
Revenue	145	150	n/a	n/a
Cost of revenue	53.5	55.1	n/a	n/a
Gross profit	91.5	94.6	n/a	n/a
Gross margin	63.1%	63.2%	n/a
Selling, general and administrative	42.0	32.9	n/a	n/a
Operating income	49.5	61.7	n/a	n/a
Operating margin	34.1%	41.2%	n/a
Interest expense	17.3	19.3	n/a	n/a
Pre-tax income	36.6	46.7	n/a	n/a
Income tax	8.9	14.8	n/a	n/a
Effective tax rate	24.3%	31.6%	n/a
Net income	27.7	31.9	n/a	n/a
Net margin	19.1%	21.3%	n/a
Diluted EPS	$0.71	$0.82	n/a	n/a

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

Line	Q1 FY2024	Q4 FY2023	A year earlier	Change on the year
Operating cash flow	61.9	73.3	n/a	n/a
Capital expenditure	0.6	0.2	n/a	n/a
Free cash flow	61.4	73.2	n/a	n/a
Free cash flow margin	42.3%	48.9%	n/a
Cash from investing	-18.1	-25.1	n/a	n/a
Cash from financing	-54.1	-67.8	n/a	n/a
Depreciation and amortisation	35.4	35.5	n/a	n/a
Share-based compensation	7.5	7.0	n/a	n/a
Diluted shares, weighted	41m	41m	n/a	n/a
Shares outstanding at period end	33m	32m	n/a	n/a

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

Line	Q1 FY2024	Q4 FY2023	A year earlier	Change on the year
Shareholders' equity	222	195	n/a	n/a
Debt	623	667	n/a	n/a
Operating lease liabilities	5.9	6.1	n/a	n/a
Other liabilities	263	275	n/a	n/a
Total liabilities and equity	1,114	1,143	n/a	n/a
Fixed assets	15.5	16.0	n/a	n/a
Goodwill	134	134	n/a	n/a
Intangible assets	387	422	n/a	n/a
Investments	89.4	71.6	n/a	n/a
Cash and equivalents	229	239	n/a	n/a
Receivables	175	180	n/a	n/a
Inventory	31.3	32.3	n/a	n/a
Other assets	53.7	49.4	n/a	n/a
Total assets	1,114	1,143	n/a	n/a

Questions

What was Collegium Pharmaceutical's revenue in Q1 FY2024?

Collegium Pharmaceutical (COLL) reported revenue of $145 million for Q1 FY2024, the quarter ended 31 March 2024, up 0.1% on the same quarter a year earlier.

How much did Collegium Pharmaceutical earn in Q1 FY2024?

Net income for Q1 FY2024 was $28 million, and diluted earnings per share $0.71.

When did Collegium Pharmaceutical report Q1 FY2024 results?

Collegium Pharmaceutical filed its 10-Q for the quarter ended 31 March 2024 with the SEC on 9 May 2024.

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026
Revenue	137	150	145	145	159	182	178	188	209	205	194	200
Cost of revenue	56.4	55.1	53.5	54.5	62.5	83.7	80.4	79.6	80.2	77.1	76.3	89.6
Gross profit	80.3	94.6	91.5	90.8	96.8	98.3	97.3	108	129	128	117	110
Gross margin	59%	63%	63%	63%	61%	54%	55%	58%	62%	62%	61%	55%
SG&A	35.3	32.9	42.0	43.3	62.0	63.1	76.4	73.6	67.1	67.6	86.3	107
Operating income	45.0	61.7	49.5	47.5	34.8	38.1	21.7	35.1	62.1	60.8	30.9	3.7
Operating margin	33%	41%	34%	33%	22%	21%	12%	19%	30%	30%	16%	2%
Interest expense	20.8	19.3	17.3	15.6	18.4	22.7	20.8	20.5	21.8	19.3	15.9	19.5
Pre-tax income	28.8	46.7	36.6	29.1	15.6	17.3	3.1	17.0	43.4	29.0	18.7	-13.5
Tax rate	28%	32%	24%	33%	40%	27%	23%	30%	27%	42%	23%	n/a
Net income	20.6	31.9	27.7	19.6	9.3	12.5	2.4	12.0	31.5	17.0	14.5	-15.1
Net margin	15%	21%	19%	13%	6%	7%	1%	6%	15%	8%	7%	-8%
Diluted EPS	$0.53	$0.82	$0.71	$0.52	$0.27	$0.36	$0.07	$0.34	$0.84	$0.46	$0.40	-$0.46
Operating cash flow	74.0	73.3	61.9	67.4	-9.0	84.6	55.4	72.4	78.4	123	57.1	71.3
Capital expenditure	0.1	0.2	0.6	0.3	0.2	0.6	0.8	0.1	0.2	0.7	0.3	0.5
Free cash flow	74.0	73.2	61.4	67.1	-9.2	84.1	54.6	72.4	78.2	122	56.8	70.8
Buybacks	n/a	n/a	n/a	n/a	0.0	n/a	n/a	25.1	0.0	n/a	n/a	0.0
Shares outstanding	33m	32m	33m	32m	32m	31m	32m	32m	32m	32m	32m	32m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

Each quarter as filed, linked to its filing.

Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 31 March 2024, filed 9 May 2024, accession 0001558370-24-007601: the filing on EDGAR. All of Collegium Pharmaceutical, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install